ReviewDialogues in clinical neuroscience2009
Personalized medicine in psychiatry: ethical challenges and opportunities.
Review in Dialogues in clinical neuroscience, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A Narrative Review of Ethical Issues in Precision Psychiatry: Mapping Unresolved Tensions Across Modalities.Journal of personalized medicine · 2026Review
- The Impact of Drug Delivery Systems on Pharmacokinetics and Drug-Drug Interactions in Neuropsychiatric Treatment.Cureus · 2025Review
- Perspectives on Precision Psychiatry Using Antipsychotics in the Management of Bipolar Disorder.Brain sciences · 2025Review
- Hierarchical taxonomy of psychopathology and personalized mental health treatment selection.Frontiers in psychiatry · 2025Review
- Heterogeneity in response to treatment across tinnitus phenotypes.Scientific reports · 2024Article
- Toward Precision Medicine in ADHD.Frontiers in behavioral neuroscience · 2022Review
- Four Actionable Bottlenecks and Potential Solutions to Translating Psychiatric Genetics Research: An Expert Review.Public health genomics · 2020Review
- Physician View and Experience of the Diagnosis of Autism Spectrum Disorder in Young Children.Frontiers in psychiatry · 2019Article
- Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?Addiction (Abingdon, England) · 2017Review
- Neurotechnological assessment of consciousness disorders: five ethical imperatives.Dialogues in clinical neuroscience · 2016Review
- Making Sense of Blood-Based Proteomics and Metabolomics in Psychiatric Research.The international journal of neuropsychopharmacology · 2016Review
- Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.Pharmacogenomics and personalized medicine · 2016Review
- 'Personalised evidence' for personalised healthcare: integration of a clinical librarian into mental health services - a feasibility study.Psychiatric bulletin (2014) · 2014Article
- 31-year-old female shows marked improvement in depression, agitation, and panic attacks after genetic testing was used to inform treatment.Case reports in psychiatry · 2014Article
- Personalizing health care: feasibility and future implications.BMC medicine · 2013Review
- Polypharmacy in psychiatry: a review.Mens sana monographs · 2013Article
- Personalized treatment of alcohol dependence.Current psychiatry reports · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenomic developments hold promise for personalized medicine in psychiatry with adjusted therapeutic doses, predictable responses, reduced adverse drug reactions, early diagnosis, and personal health planning. The prospects are exciting, but at the same time, these new techniques stand faced with important scientific, ethical, legal, and social challenges that need to be met in order for the scientific advances to be responsibly applied. This review discusses the ethical balance between challenge and opportunity of personalized medicine in psychiatry under the aspects of adequacy, cost:benefit ratio, and therapeutic equity. It is argued that the promising nature of these therapeutic possibilities makes it all the more important to avoid exaggerating the expectations, and that a sophisticated social infrastructure needs to be developed in order to ensure the realistic and responsible application of personalized medicine in psychiatry.
Indexed as
Identifiers
20135900PMC3181935What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.